We fight to improve the lives
of everyone affected by epilepsy

EMA public hearing on valproate-based medicines open for applications from EU citizens

14 Jul 2017

The European Medicines Agency (EMA) is holding a public hearing on medicines containing valproate on 26 September 2017 at its London offices.

The EMA assesses and oversees the safety of medicines in the EU. The announced public hearing is part of the EMA’s review into the use of valproate-based medicines in women who are pregnant or of childbearing age.

Valproate-based medicines are used to treat a number of conditions, including epilepsy. Sodium valproate can be very effective in treating epilepsy for some people. However, if taken by women during pregnancy, it can increase the risks of birth defects in babies.

Public hearings are a way in which the EMA can hear the experiences of members of the EU public into different topics.

The EMA is hoping to hear from people about their thoughts on the risks of taking valproate medicines during pregnancy. They also want people’s opinions on current measures to reduce the risk of women using these medicines during pregnancy and thoughts on future measures.

People can apply to attend the public hearing by filling out an application form which can be downloaded from the EMA website. To register your interest, you need to complete the application form and send it in to the EMA at publichearings@ema.europa.eu by 25 August 2017. The EMA has said that due to space restrictions, they can’t accept all applications. However, the public hearing will be broadcast live on 26 September on the EMA’s website.

You can apply to be a speaker or an observer at the public hearing. The EMA has provided a summary of the safety concerns around valproate medicines and a list of questions the public hearing will look into. There is also an information video about the public hearing process.

This is the first time the EMA has held a public hearing as part of a medicine review. EMA’s Camelia Enachioiu said: “Public hearings will give EU citizens a voice in the evaluation of the safety of medicines and empower them to express their views.”

She added that the EMA’s safety committee decided to organise a public hearing into valproate-based medicines as part of its review to listen directly to people’s experiences. “These contributions can be taken into account in the committee’s recommendation.”

There is more information on sodium valproate on the Epilepsy Action website. For full details on the EMA’s public hearing into the safety of valproate-based medicines, visit the EMA website.


You may also be interested in…

European Medicines Agency to review use of valproate medicines in women of childbearing age or during pregnancy

The European Medicines Agency (EMA) has decided to review the use of valproate-based medicines in women who are pregnant or of childbearing age.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
9 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.